Bristol-Myers Braces For Blow In Class Action Suit

Law360, New York (January 23, 2006, 12:00 AM EST) -- For Bristol-Myers Squibb Co., when it rains it pours. In its latest effort to snuff out an unrelenting barrage of complaints from shareholders, the company has set aside $185 million in anticipation of settling a securities class action lawsuit over an experimental heart drug the company touted as a future blockbuster that later proved to be potentially fatal.

The lawsuit, filed in a federal court in New Jersey in 2000, alleges the pharmaceutical giant continued to hype its experimental heart drug Vanlev despite poor clinical trial...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.